{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:00:15Z","timestamp":1794096015261,"version":"4.8.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T00:00:00Z","timestamp":1673568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005187","name":"University of Athens","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>JAK inhibitors (JAKi) are new targeted-synthetic drugs, approved for various immune-mediated inflammatory diseases (IMIDs), including inflammatory arthritides (rheumatoid arthritis\u2014RA, psoriatic arthritis\u2014PsA, ankylosing spondylitis\u2014AS) and ulcerative colitis (UC). JAKi have been associated with increased risk for herpes zoster (HZ), but the relative risk among different JAKi in these IMIDs remains unclear. We aimed to systematically review the incidence of HZ among RA, PsA, AS and UC patients treated with the approved doses of tofacitinib (TOFA), baricitinib (BARI) or upadacitinib (UPA). PubMed, Embase, Scopus, Cochrane and Web-of-Science were searched up to 30 March 2022. Clinical trials and real-world studies (RWS) were included. Outcomes assessed were the incidence rate (\/100 patient-years) or\/and cumulative incidence of HZ. From 1710 records, 53 clinical trials and 25 RWS were included (RA: 54, PsA: 8, AS: 4, and UC: 12). In clinical trials, the HZ-incidence was higher in TOFA-treated patients with RA (2.2\u20137.1\/100 patient-years) or UC (1.3\u20137.6\/100 patient-years) compared to PsA (1.7\/100 patient-years), and with higher doses of TOFA in UC (10\u00a0mg\/twice daily: 3.2\u20137.6\/100 patient-years vs. 5\u00a0mg\/twice daily: 1.3\u20132.3\/100 patient-years). Evidence for HZ-risk in JAKi-treated patients with AS and in UPA-treated patients was limited. The HZ-incidence between TOFA and BARI groups in 2 RA RWS did not differ significantly. Concomitant glucocorticoid, but not methotrexate, use in RA increased the HZ-risk. This systematic review showed higher HZ-risk in RA or UC than PsA patients treated with TOFA, in those treated with higher TOFA doses or with concomitant glucocorticoids. Preventive measures and monitoring of JAKi-treated patients with IMIDs are essential in daily practice.<\/jats:p>","DOI":"10.1007\/s00296-022-05270-6","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T02:02:30Z","timestamp":1673575350000},"page":"421-435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1310-7902","authenticated-orcid":false,"given":"Chrysoula G.","family":"Gialouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4648-1578","authenticated-orcid":false,"given":"Savvina","family":"Moustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-5389","authenticated-orcid":false,"given":"Emilia","family":"Hadziyannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-3863","authenticated-orcid":false,"given":"Dimitrios","family":"Vassilopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,13]]},"reference":[{"issue":"12","key":"5270_CR1","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1016\/j.mayocp.2017.10.009","volume":"92","author":"K Kawai","year":"2017","unstructured":"Kawai K, Yawn BP (2017) Risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clin Proc 92(12):1806\u20131821","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"5270_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/2051013615599151","volume":"3","author":"RW Johnson","year":"2015","unstructured":"Johnson RW, Alvarez-Pasquin MJ, Bijl M, Franco E, Gaillat J, Clara JG et al (2015) Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Therapeutic Adva Vaccines 3(4):109\u2013120","journal-title":"Therapeutic Adva Vaccines"},{"issue":"8","key":"5270_CR3","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/art.23112","volume":"57","author":"AL Smitten","year":"2007","unstructured":"Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA et al (2007) The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 57(8):1431\u20131438","journal-title":"Arthritis Rheum"},{"issue":"9","key":"5270_CR4","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.39670","volume":"68","author":"H Yun","year":"2016","unstructured":"Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW et al (2016) Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol (Hoboken, NJ) 68(9):2328\u20132337","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"7","key":"5270_CR5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jama.2009.146","volume":"301","author":"A Strangfeld","year":"2009","unstructured":"Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C et al (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301(7):737\u2013744","journal-title":"JAMA"},{"issue":"7","key":"5270_CR6","first-page":"1432","volume":"40","author":"J Galloway","year":"2022","unstructured":"Galloway J, Raine T, Rivett L, Roberts J, Dews SA, Choy EH (2022) Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination. Clin Exp Rheumatol 40(7):1432\u20131441","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"5270_CR7","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1177\/0961203320923739","volume":"29","author":"CC Mok","year":"2020","unstructured":"Mok CC, Tse SM, Chan KL, Ho LY (2020) Prevalence and risk factors of herpes zoster infection in patients with biopsy proven lupus nephritis undergoing immunosuppressive therapies. Lupus 29(8):836\u2013844","journal-title":"Lupus"},{"issue":"1","key":"5270_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s13075-018-1742-5","volume":"20","author":"D Schub","year":"2018","unstructured":"Schub D, Assmann G, Sester U, Sester M, Schmidt T (2018) VZV-specific T-cell levels in patients with rheumatic diseases are reduced and differentially influenced by antirheumatic drugs. Arthritis Res Ther 20(1):252","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 1","key":"5270_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.31138\/mjr.31.1.129","volume":"31","author":"K Thomas","year":"2020","unstructured":"Thomas K, Vassilopoulos D (2020) Infections in patients with rheumatoid arthritis in the era of targeted synthetic therapies. Mediterr J Rheumatol 31(Suppl 1):129\u2013136","journal-title":"Mediterr J Rheumatol"},{"issue":"Suppl 1","key":"5270_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/rheumatology\/key276","volume":"58","author":"GE Fragoulis","year":"2019","unstructured":"Fragoulis GE, McInnes IB, Siebert S (2019) JAK-inhibitors new players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford) 58(Suppl 1):43\u201354","journal-title":"Rheumatology (Oxford)"},{"issue":"14","key":"5270_CR11","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1007\/s00018-017-2520-2","volume":"74","author":"N Raftery","year":"2017","unstructured":"Raftery N, Stevenson NJ (2017) Advances in anti-viral immune defence: revealing the importance of the IFN JAK\/STAT pathway. Cell Mol Life Sci 74(14):2525\u20132535","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"5270_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O\u2019Shea JJ (2009) Janus kinases in immune cell signaling. Immunol Rev 228(1):273\u2013287","journal-title":"Immunol Rev"},{"issue":"1","key":"5270_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1128\/CMR.18.1.70-80.2005","volume":"18","author":"S Hambleton","year":"2005","unstructured":"Hambleton S, Gershon AA (2005) Preventing varicella-zoster disease. Clin Microbiol Rev 18(1):70\u201380","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"5270_CR14","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1046\/j.1365-2249.1997.4001304.x","volume":"108","author":"N Sharfe","year":"1997","unstructured":"Sharfe N, Dadi HK, O\u2019Shea JJ, Roifman CM (1997) Jak3 activation in human lymphocyte precursor cells. Clin Exp Immunol 108(3):552\u2013556","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"5270_CR15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL (2017) The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 13(4):234\u2013243","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"5270_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004901","volume":"11","author":"MC Verweij","year":"2015","unstructured":"Verweij MC, Wellish M, Whitmer T, Malouli D, Lapel M, Jonjic S et al (2015) Varicella viruses inhibit interferon-stimulated JAK-STAT signaling through multiple mechanisms. PLoS Pathog 11(5):e1004901","journal-title":"PLoS Pathog"},{"issue":"19","key":"5270_CR17","doi-asserted-by":"publisher","first-page":"11634","DOI":"10.1128\/JVI.01945-14","volume":"88","author":"MA Nagel","year":"2014","unstructured":"Nagel MA, James SF, Traktinskiy I, Wyborny A, Choe A, Rempel A et al (2014) Inhibition of phosphorylated-STAT1 nuclear translocation and antiviral protein expression in human brain vascular adventitial fibroblasts infected with varicella-zoster virus. J Virol 88(19):11634\u201311637","journal-title":"J Virol"},{"issue":"2","key":"5270_CR18","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1073\/pnas.1114232109","volume":"109","author":"N Sen","year":"2012","unstructured":"Sen N, Che X, Rajamani J, Zerboni L, Sung P, Ptacek J et al (2012) Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis. Proc Natl Acad Sci USA 109(2):600\u2013605","journal-title":"Proc Natl Acad Sci USA"},{"key":"5270_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/82_2022_254","author":"A Abendroth","year":"2022","unstructured":"Abendroth A, Slobedman B (2022) Modulation of MHC and MHC-like molecules by varicella zoster virus. Curr Top Microbiol Immunol. https:\/\/doi.org\/10.1007\/82_2022_254","journal-title":"Curr Top Microbiol Immunol"},{"issue":"10","key":"5270_CR20","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP et al (2019) A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 58(10):1755\u20131766","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"5270_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","volume":"18","author":"MA Adas","year":"2022","unstructured":"Adas MA, Alveyn E, Cook E, Dey M, Galloway JB, Bechman K (2022) The infection risks of JAK inhibition. Expert Rev Clin Immunol 18(3):253\u2013261","journal-title":"Expert Rev Clin Immunol"},{"key":"5270_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001374","author":"A Kerschbaumer","year":"2020","unstructured":"Kerschbaumer A, Smolen JS, Nash P, Doerner T, Dougados M, Fleischmann R et al (2020) Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2020-001374","journal-title":"RMD Open"},{"key":"5270_CR23","unstructured":"Cochrane Handbook for systematic reviews of interventions https:\/\/training.cochrane.org\/handbook Accessed 9 July 2022."},{"key":"5270_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700","journal-title":"BMJ"},{"key":"5270_CR25","unstructured":"PROSPERO-International prospective register of systematic reviews https:\/\/www.crd.york.ac.uk\/prospero\/ Accessed 7 July 2022."},{"key":"5270_CR26","unstructured":"Higgins JPT SJ, Page MJ, Elbers RG, Sterne JAC. Chapter 8: assessing risk of bias in a randomized trial. cochrane handbook for systematic reviews of interventions\u00a0version 6.3. Cochrane, 2022. www.training.cochrane.org\/handbook Accessed Feb 2022."},{"key":"5270_CR27","unstructured":"Wells GA SB, O\u2019Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"issue":"1","key":"5270_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/jebm.12141","volume":"8","author":"X Zeng","year":"2015","unstructured":"Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F et al (2015) The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med 8(1):2\u201310","journal-title":"J Evid Based Med"},{"key":"5270_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002012","author":"R Fleischmann","year":"2022","unstructured":"Fleischmann R, Mysler E, Bessette L, Peterfy CG, Durez P, Tanaka Y et al (2022) Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2021-002012","journal-title":"RMD Open"},{"issue":"1","key":"5270_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13075-020-02387-6","volume":"23","author":"H Kameda","year":"2021","unstructured":"Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Yokoyama M et al (2021) Efficacy and safety of upadacitinib over 84 weeks in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE). Arthritis Res Ther 23(1):9","journal-title":"Arthritis Res Ther"},{"key":"5270_CR31","unstructured":"Julian PT Higgins JS, Matthew J Page, Jonathan AC Sterne. Revised Cochrane risk of bias tool for randomized trials (RoB 2.0) 2016 https:\/\/www.unisa.edu.au\/contentassets\/72bf75606a2b4abcaf7f17404af374ad\/rob2-0_indiv_main_guidance.pdf Accessed 16 11 2022."},{"issue":"11","key":"5270_CR32","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C et al (2019) Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol (Hoboken, NJ) 71(11):1788\u20131800","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"4","key":"5270_CR33","first-page":"732","volume":"38","author":"Z Li","year":"2020","unstructured":"Li Z, Hu J, Bao C, Li X, Li X, Xu J et al (2020) Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study. Clin Exp Rheumatol 38(4):732\u2013741","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"5270_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/14397595.2017.1307899","volume":"28","author":"Y Tanaka","year":"2018","unstructured":"Tanaka Y, Ishii T, Cai Z, Schlichting D, Rooney T, Macias W (2018) Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study. Mod Rheumatol 28(1):20\u201329","journal-title":"Mod Rheumatol"},{"issue":"4","key":"5270_CR35","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s40744-020-00231-6","volume":"7","author":"Y Yang","year":"2020","unstructured":"Yang Y, Li XF, Zhang X, Bao CD, Hu JK, Xu JH et al (2020) Efficacy and safety of baricitinib in Chinese rheumatoid arthritis patients and the subgroup analyses: results from study RA-BALANCE. Rheumatol Ther 7(4):851\u2013866","journal-title":"Rheumatol Ther"},{"issue":"4","key":"5270_CR36","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316\u2013326","journal-title":"N Engl J Med"},{"issue":"7","key":"5270_CR37","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, Van Der Heijde D, Weinblatt ME, Del Carmen ML, Gonzaga JR et al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376(7):652\u2013662","journal-title":"N Engl J Med"},{"issue":"6","key":"5270_CR38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD et al (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367(6):495\u2013507","journal-title":"N Engl J Med"},{"issue":"25","key":"5270_CR39","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370(25):2377\u20132386","journal-title":"N Engl J Med"},{"issue":"1","key":"5270_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","volume":"21","author":"J Wollenhaupt","year":"2019","unstructured":"Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K et al (2019) Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther 21(1):89","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"5270_CR41","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/acr.23769","volume":"71","author":"JR Curtis","year":"2019","unstructured":"Curtis JR, Xie F, Yang S, Bernatsky S, Chen L, Yun H et al (2019) Risk for herpes zoster in tofacitinib-treated rheumatoid arthritis patients with and without concomitant methotrexate and glucocorticoids. Arthritis Care Res 71(9):1249\u20131254","journal-title":"Arthritis Care Res"},{"issue":"3","key":"5270_CR42","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C et al (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65(3):559\u2013570","journal-title":"Arthritis Rheum"},{"issue":"6","key":"5270_CR43","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/art.40803","volume":"71","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini CAF et al (2019) Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty-four\u2013month phase III study. Arthritis Rheumatol 71(6):878\u2013891","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"5270_CR44","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E et al (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159(4):253\u2013261","journal-title":"Ann Intern Med"},{"key":"5270_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13075-016-0932-2","volume":"18","author":"H Yamanaka","year":"2016","unstructured":"Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S et al (2016) Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther 18:34","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"5270_CR46","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3906\/sag-2007-123","volume":"51","author":"E Bilgin","year":"2021","unstructured":"Bilgin E, Ceylan F, Duran E, Fariso\u011fullari B, B\u00f6lek E, Yardimci GK et al (2021) Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience. Turkish J Med Sci 51(1):297\u2013308","journal-title":"Turkish J Med Sci"},{"issue":"10","key":"5270_CR47","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","volume":"75","author":"JR Curtis","year":"2016","unstructured":"Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL (2016) Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis 75(10):1843\u20131847","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5270_CR48","first-page":"1","volume":"4","author":"SK Chen","year":"2020","unstructured":"Chen SK, Lee H, Jin Y, Liu J, Kim SC (2020) Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitus. Rheumatol Adva Prac 4(2):1\u201311","journal-title":"Rheumatol Adva Prac"},{"issue":"5","key":"5270_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177057","volume":"12","author":"N Iwamoto","year":"2017","unstructured":"Iwamoto N, Tsuji S, Takatani A, Shimizu T, Fukui S, Umeda M et al (2017) Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. PLoS ONE 12(5):e0177057","journal-title":"PLoS ONE"},{"issue":"3","key":"5270_CR50","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/acr2.11232","volume":"3","author":"JM Kremer","year":"2021","unstructured":"Kremer JM, Bingham CO, Cappelli LC, Greenberg JD, Madsen AM, Geier J et al (2021) Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-Based rheumatoid arthritis registry. ACR Open Rheumatol 3(3):173\u2013184","journal-title":"ACR Open Rheumatol"},{"issue":"2","key":"5270_CR51","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1016\/S2665-9913(19)30137-7","volume":"2","author":"A Pawar","year":"2020","unstructured":"Pawar A, Desai RJ, Gautam N, Kim SC (2020) Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. Lancet Rheumatol 2(2):e84\u2013e98","journal-title":"Lancet Rheumatol"},{"issue":"12","key":"5270_CR52","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1007\/s10067-019-04721-z","volume":"38","author":"S Mori","year":"2019","unstructured":"Mori S, Ueki Y (2019) Outcomes of dose reduction, withdrawal, and restart of tofacitinib in patients with rheumatoid arthritis: a prospective observational study. Clin Rheumatol 38(12):3391\u20133400","journal-title":"Clin Rheumatol"},{"issue":"6","key":"5270_CR53","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF Van Vollenhoven","year":"2012","unstructured":"Van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Meijide JAG, Wagner S et al (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367(6):508\u2013519","journal-title":"N Engl J Med"},{"issue":"10093","key":"5270_CR54","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z et al (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. The Lancet 390(10093):457\u2013468","journal-title":"The Lancet"},{"issue":"7","key":"5270_CR55","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1002\/art.24567","volume":"60","author":"JM Kremer","year":"2009","unstructured":"Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D et al (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60(7):1895\u20131905","journal-title":"Arthritis Rheum"},{"issue":"4","key":"5270_CR56","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3109\/14397595.2014.995875","volume":"25","author":"Y Tanaka","year":"2015","unstructured":"Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S (2015) Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: A 12-week, randomized, phase 2 study. Mod Rheumatol 25(4):514\u2013521","journal-title":"Mod Rheumatol"},{"issue":"41","key":"5270_CR57","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022504","volume":"99","author":"YJ Chen","year":"2020","unstructured":"Chen YJ, Chen YM, Huang WN, Chen HH, Liao TL, Chen JP et al (2020) Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan. Medicine 99(41):e22504","journal-title":"Medicine"},{"issue":"1","key":"5270_CR58","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13075-021-02582-z","volume":"23","author":"N Iwamoto","year":"2021","unstructured":"Iwamoto N, Sato S, Kurushima S, Michitsuji T, Nishihata S, Okamoto M et al (2021) Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis. Arthritis Res Ther 23(1):197","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"5270_CR59","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1136\/annrheumdis-2020-219699","volume":"80","author":"Y Miyazaki","year":"2021","unstructured":"Miyazaki Y, Nakano K, Nakayamada S, Kubo S, Inoue Y, Fujino Y et al (2021) Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting. Ann Rheum Dis 80(9):1130\u20131136","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5270_CR60","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40744-018-0097-3","volume":"5","author":"S Cohen","year":"2018","unstructured":"Cohen S, Curtis JR, DeMasi R, Chen Y, Fan H, Soonasra A et al (2018) Worldwide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis. Rheumatol Therapy 5(1):283\u2013291","journal-title":"Rheumatol Therapy"},{"issue":"3","key":"5270_CR61","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.39953","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M et al (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69(3):506\u2013517","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"5270_CR62","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","volume":"74","author":"EC Keystone","year":"2015","unstructured":"Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY et al (2015) Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 74(2):333\u2013340","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5270_CR63","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3899\/jrheum.161161","volume":"45","author":"EC Keystone","year":"2018","unstructured":"Keystone EC, Genovese MC, Schlichting DE, De La Torre I, Beattie SD, Rooney TP et al (2018) Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis. J Rheumatol 45(1):14\u201321","journal-title":"J Rheumatol"},{"issue":"3","key":"5270_CR64","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3899\/jrheum.150613","volume":"43","author":"Y Tanaka","year":"2016","unstructured":"Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T et al (2016) Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol 43(3):504\u2013511","journal-title":"J Rheumatol"},{"issue":"1","key":"5270_CR65","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, Van Der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J et al (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76(1):88\u201395","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"5270_CR66","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L et al (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374(13):1243\u20131252","journal-title":"N Engl J Med"},{"issue":"4","key":"5270_CR67","doi-asserted-by":"publisher","first-page":"868","DOI":"10.55563\/clinexprheumatol\/pudtpo","volume":"39","author":"GM Guidelli","year":"2021","unstructured":"Guidelli GM, Viapiana O, Luciano N, De Santis M, Boffini N, Quartuccio L et al (2021) Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study. Clin Exp Rheumatol 39(4):868\u2013873","journal-title":"Clin Exp Rheumatol"},{"key":"5270_CR68","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211014019","author":"G Tesei","year":"2021","unstructured":"Tesei G, Cometi L, Nacci F, Terenzi R, Tofani L, Capassoni M et al (2021) Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience. Therapeutic Adva Musculoskeletal Dis. https:\/\/doi.org\/10.1177\/1759720X211014019","journal-title":"Therapeutic Adva Musculoskeletal Dis"},{"key":"5270_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-78925-8","author":"N Takahashi","year":"2020","unstructured":"Takahashi N, Asai S, Kobayakawa T, Kaneko A, Watanabe T, Kato T et al (2020) Predictors for clinical effectiveness of baricitinib in rheumatoid arthritis patients in routine clinical practice: data from a Japanese multicenter registry. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-020-78925-8","journal-title":"Sci Rep"},{"issue":"11","key":"5270_CR70","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","volume":"19","author":"L Peng","year":"2020","unstructured":"Peng L, Xiao K, Ottaviani S, Stebbing J, Wang YJ (2020) A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for baricitinib. Expert Opin Drug Saf 19(11):1505\u20131511","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"5270_CR71","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","volume":"78","author":"RM Fleischmann","year":"2019","unstructured":"Fleischmann RM, Genovese MC, Enejosa JV, Mysler E, Bessette L, Peterfy C et al (2019) Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis 78(11):1454\u20131462","journal-title":"Ann Rheum Dis"},{"issue":"10139","key":"5270_CR72","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, Van den Bosch F, Kivitz A, Bessette L, Li Y et al (2018) Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England) 391(10139):2503\u20132512","journal-title":"Lancet (London, England)"},{"issue":"10139","key":"5270_CR73","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y et al (2018) Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet (London, England) 391(10139):2513\u20132524","journal-title":"Lancet (London, England)"},{"issue":"11","key":"5270_CR74","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1093\/rheumatology\/keaa084","volume":"59","author":"H Kameda","year":"2020","unstructured":"Kameda H, Takeuchi T, Yamaoka K, Oribe M, Kawano M, Zhou Y et al (2020) Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb\/III study. Rheumatology (Oxford) 59(11):3303\u20133313","journal-title":"Rheumatology (Oxford)"},{"issue":"16","key":"5270_CR75","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL, Haraoui B, Rischmueller M, Khan N et al (2020) Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med 383(16):1511\u20131521","journal-title":"N Engl J Med"},{"issue":"12","key":"5270_CR76","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1111\/1756-185X.14235","volume":"24","author":"X Zeng","year":"2021","unstructured":"Zeng X, Zhao D, Radominski SC, Keiserman M, Lee CK, Meerwein S et al (2021) Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy. Int J Rheum Dis 24(12):1530\u20131539","journal-title":"Int J Rheum Dis"},{"issue":"10","key":"5270_CR77","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/art.41384","volume":"72","author":"R van Vollenhoven","year":"2020","unstructured":"van Vollenhoven R, Takeuchi T, Pangan AL, Friedman A, Mohamed MF, Chen S et al (2020) Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. Arthritis Rheumatology (Hoboken, NJ) 72(10):1607\u20131620","journal-title":"Arthritis Rheumatology (Hoboken, NJ)"},{"issue":"10188","key":"5270_CR78","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI et al (2019) Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet (London, England) 393(10188):2303\u20132311","journal-title":"Lancet (London, England)"},{"issue":"3","key":"5270_CR79","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1080\/14397595.2020.1847776","volume":"31","author":"T Takeuchi","year":"2021","unstructured":"Takeuchi T, Rischmueller M, Blanco R, Xavier RM, Ueki Y, Atsumi T et al (2021) Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-na\u00efve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study. Mod Rheumatol 31(3):534\u2013542","journal-title":"Mod Rheumatol"},{"issue":"16","key":"5270_CR80","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A et al (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF Inhibitors. N Engl J Med 377(16):1525\u20131536","journal-title":"N Engl J Med"},{"issue":"16","key":"5270_CR81","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F et al (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377(16):1537\u20131550","journal-title":"N Engl J Med"},{"issue":"3","key":"5270_CR82","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s40744-020-00209-4","volume":"7","author":"P Nash","year":"2020","unstructured":"Nash P, Coates LC, Kivitz AJ, Mease PJ, Gladman DD, Covarrubias-Cobos JA et al (2020) Safety and efficacy of tofacitinib in patients with active psoriatic arthritis: interim analysis of opal balance, an open-label long-term extension study. Rheumatol Therapy 7(3):553\u2013580","journal-title":"Rheumatol Therapy"},{"issue":"1","key":"5270_CR83","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S2665-9913(20)30339-8","volume":"3","author":"P Nash","year":"2021","unstructured":"Nash P, Mease PJ, Fleishaker D, Wu J, Coates LC, Behrens F et al (2021) Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL balance. Lancet Rheumatol 3(1):e28\u2013e39","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"5270_CR84","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","volume":"80","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Lertratanakul A, Anderson JK, Papp K, Van Den Bosch F, Tsuji S et al (2021) Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis 80(3):312\u2013320","journal-title":"Ann Rheum Dis"},{"issue":"13","key":"5270_CR85","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","volume":"384","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Anderson JK, Magrey M, Merola JF, Liu Y, Kishimoto M et al (2021) Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med 384(13):1227\u20131239","journal-title":"N Engl J Med"},{"issue":"2","key":"5270_CR86","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s40744-021-00305-z","volume":"8","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Lertratanakul A, Papp KA, van den Bosch FE, Tsuji S, Dokoupilova E et al (2021) Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 56-week data from the randomized controlled phase 3 SELECT-PsA 2 study. Rheumatol Therapy 8(2):903\u2013919","journal-title":"Rheumatol Therapy"},{"issue":"8","key":"5270_CR87","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D Van Der Heijde","year":"2017","unstructured":"Van Der Heijde D, Deodhar A, Wei JC, Drescher E, Fleishaker D, Hendrikx T et al (2017) Tofacitinib in patients with ankylosing spondylitis: A phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis 76(8):1340\u20131347","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"5270_CR88","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","volume":"80","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D et al (2021) Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 80(8):1004\u20131013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5270_CR89","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/art.41911","volume":"74","author":"A Deodhar","year":"2022","unstructured":"Deodhar A, van der Heijde D, Sieper J, Van den Bosch F, Maksymowych WP, Kim TH et al (2022) Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a double-blind, placebo-controlled study and open-label extension. Arthritis Rheumatol 74(1):70\u201380","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"5270_CR90","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1112168","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S et al (2012) Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 367(7):616\u2013624","journal-title":"N Engl J Med"},{"issue":"18","key":"5270_CR91","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, D\u2019Haens GR, Vermeire S, Schreiber S et al (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376(18):1723\u20131736","journal-title":"N Engl J Med"},{"issue":"4","key":"5270_CR92","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/apt.16712","volume":"55","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV Jr, Hart A et al (2022) Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther 55(4):464\u2013478","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"5270_CR93","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.dld.2021.11.009","volume":"54","author":"I Avni-Biron","year":"2022","unstructured":"Avni-Biron I, Bar-Gil Shitrit A, Koslowsky B, Levartovsky A, Kopylov U, Weisshof R et al (2022) Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel. Digestive Liver Dis 54(2):192\u2013197","journal-title":"Digestive Liver Dis"},{"issue":"8","key":"5270_CR94","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.cgh.2020.06.050","volume":"19","author":"P Deepak","year":"2021","unstructured":"Deepak P, Alayo QA, Khatiwada A, Lin B, Fenster M, Dimopoulos C et al (2021) Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis. Clin Gastroenterol Hepatol 19(8):1592\u2013601.e3","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"5270_CR95","doi-asserted-by":"publisher","first-page":"354","DOI":"10.34172\/aim.2021.52","volume":"24","author":"M Jameshorani","year":"2021","unstructured":"Jameshorani M, Vahedi H, Sadeghi A, Sima AR, Anushiravani A, Nateghi Beige H et al (2021) Efficacy and safety of tofacitinib for treatment of moderate to severe active ulcerative colitis: first report from Iran. Arch Iran Med 24(5):354\u2013363","journal-title":"Arch Iran Med"},{"issue":"10","key":"5270_CR96","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1097\/MEG.0000000000002028","volume":"33","author":"T Straatmijer","year":"2021","unstructured":"Straatmijer T, van Gennep S, Duijvestein M, Ponsioen CIJ, Gecse KB, D\u2019Haens GR et al (2021) Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis. Eur J Gastroenterol Hepatol 33(10):1288\u20131297","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"5270_CR97","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/ecco-jcc\/jjaa249","volume":"15","author":"S Vermeire","year":"2021","unstructured":"Vermeire S, Su C, Lawendy N, Kobayashi T, Sandborn WJ, Rubin DT et al (2021) Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomised RIVETING trial. J Crohns Colitis 15(7):1130\u20131141","journal-title":"J Crohns Colitis"},{"issue":"3","key":"5270_CR98","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.dld.2019.10.003","volume":"52","author":"L Lair-Mehiri","year":"2020","unstructured":"Lair-Mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I et al (2020) Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Digestive Liver Dis 52(3):268\u2013273","journal-title":"Digestive Liver Dis"},{"issue":"1","key":"5270_CR99","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjaa145","volume":"15","author":"M Chaparro","year":"2021","unstructured":"Chaparro M, Garre A, Mesonero F, Rodr\u00edguez C, Barreiro-De Acosta M, Mart\u00ednez-Cadilla J et al (2021) Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA registry. J Crohns Colitis 15(1):35\u201342","journal-title":"J Crohns Colitis"},{"issue":"8","key":"5270_CR100","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Ghosh S, Panes J, Schreiber S, D\u2019Haens G, Tanida S et al (2020) Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology 158(8):2139\u201349.e14","journal-title":"Gastroenterology"},{"issue":"1","key":"5270_CR101","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1136\/annrheumdis-2021-220651","volume":"81","author":"I Redeker","year":"2022","unstructured":"Redeker I, Albrecht K, Kekow J, Burmester GR, Braun J, Sch\u00e4fer M et al (2022) Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register. Ann Rheum Dis 81(1):41\u201347","journal-title":"Ann Rheum Dis"},{"key":"5270_CR102","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001892","author":"YJ Song","year":"2022","unstructured":"Song YJ, Cho SK, Kim H, Kim HW, Nam E, Choi CB et al (2022) Risk factors for herpes zoster in Korean patients with rheumatoid arthritis treated with JAK inhibitor: a nested case-control study. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2021-001892","journal-title":"RMD Open"},{"key":"5270_CR103","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06096-0","author":"W Choi","year":"2022","unstructured":"Choi W, Ahn SM, Kim YG, Lee CK, Yoo B, Hong S (2022) Safety of JAK inhibitor use in patients with rheumatoid arthritis who developed herpes zoster after receiving JAK inhibitors. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-022-06096-0","journal-title":"Clin Rheumatol"},{"key":"5270_CR104","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-7-5","author":"K Pavelka","year":"2020","unstructured":"Pavelka K, Szekanecz Z, Damjanov N, Ani\u0107 B, Tom\u0161i\u010d M, Mazurov V et al (2020) Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients. Drugs Context. https:\/\/doi.org\/10.7573\/dic.2020-7-5","journal-title":"Drugs Context"},{"issue":"10214","key":"5270_CR105","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Song IH, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP et al (2019) Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet (London, England) 394(10214):2108\u20132117","journal-title":"Lancet (London, England)"},{"issue":"2","key":"5270_CR106","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/apt.15555","volume":"51","author":"BE Sands","year":"2020","unstructured":"Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S et al (2020) Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Aliment Pharmacol Ther 51(2):271\u2013280","journal-title":"Aliment Pharmacol Ther"},{"key":"5270_CR107","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001595","author":"GR Burmester","year":"2021","unstructured":"Burmester GR, Nash P, Sands BE, Papp K, Stockert L, Jones TV et al (2021) Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2021-001595","journal-title":"RMD Open"},{"issue":"2","key":"5270_CR108","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1097\/RHU.0000000000001749","volume":"28","author":"C Alves","year":"2022","unstructured":"Alves C, Penedones A, Mendes D, Marques FB (2022) The risk of infections associated with JAK inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis. J Clin Rheumatol 28(2):e407\u2013e414","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"5270_CR109","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","volume":"158","author":"PA Olivera","year":"2020","unstructured":"Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L (2020) Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology 158(6):1554\u201373.e12","journal-title":"Gastroenterology"},{"issue":"5","key":"5270_CR110","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40259-018-0304-3","volume":"32","author":"F Huang","year":"2018","unstructured":"Huang F, Luo ZC (2018) Risk of adverse drug events observed with baricitinib 2 mg Versus Baricitinib 4 mg once daily for the treatment of rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. BioDrugs 32(5):415\u2013423","journal-title":"BioDrugs"},{"issue":"2","key":"5270_CR111","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10067-018-4299-4","volume":"38","author":"F Huang","year":"2019","unstructured":"Huang F, Luo ZC (2019) Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: a systematic review and meta-analysis of randomized controlled trials. Clin Rheumatol 38(2):523\u2013534","journal-title":"Clin Rheumatol"},{"issue":"10","key":"5270_CR112","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/art.40189","volume":"69","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H et al (2017) Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol (Hoboken, NJ) 69(10):1960\u20131968","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"7","key":"5270_CR113","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1002\/art.41655","volume":"73","author":"N Bing","year":"2021","unstructured":"Bing N, Zhou H, Chen X, Hirose T, Kochi Y, Tsuchida Y et al (2021) Contribution of a European-prevalent variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: results of genome-wide association study meta-analyses. Arthritis Rheumatol (Hoboken, NJ) 73(7):1155\u20131166","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"10","key":"5270_CR114","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1093\/ibd\/izy131","volume":"24","author":"KL Winthrop","year":"2018","unstructured":"Winthrop KL, Melmed GY, Vermeire S, Long MD, Chan G, Pedersen RD et al (2018) Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis 24(10):2258\u20132265","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"5270_CR115","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jaad.2019.03.017","volume":"81","author":"E Baumrin","year":"2019","unstructured":"Baumrin E, Van Voorhees A, Garg A, Feldman SR, Merola JF (2019) A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: from the medical board of the national psoriasis foundation. J Am Acad Dermatol 81(1):102\u2013110","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"5270_CR116","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","volume":"80","author":"P Nash","year":"2021","unstructured":"Nash P, Kerschbaumer A, Dorner T, Dougados M, Fleischmann RM, Geissler K et al (2021) Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis 80(1):71\u201387","journal-title":"Ann Rheum Dis"},{"key":"5270_CR117","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001395","author":"SB Cohen","year":"2020","unstructured":"Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P et al (2020) Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2020-001395","journal-title":"RMD Open"},{"issue":"3","key":"5270_CR118","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","volume":"80","author":"SB Cohen","year":"2020","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL, Zerbini CAF, Tanaka Y, Bessette L et al (2020) Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis 80(3):304\u2013311","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5270_CR119","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40744-021-00390-0","volume":"9","author":"KL Winthrop","year":"2022","unstructured":"Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL et al (2022) Clinical management of herpes zoster in patients with rheumatoid arthritis or psoriatic arthritis receiving tofacitinib treatment. Rheumatol Therapy 9(1):243\u2013263","journal-title":"Rheumatol Therapy"},{"issue":"1","key":"5270_CR120","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M et al (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79(1):39\u201352","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"5270_CR121","doi-asserted-by":"publisher","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","volume":"71","author":"TC Anderson","year":"2022","unstructured":"Anderson TC, Masters NB, Guo A, Shepersky L, Leidner AJ, Lee GM et al (2022) Use of recombinant zoster vaccine in immunocompromised adults aged >\/=19 years: recommendations of the advisory committee on immunization practices\u2014United States, 2022. MMWR Morb Mortal Wkly Rep 71(3):80\u201384","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"5270_CR122","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3899\/jrheum.171361","volume":"46","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T et al (2019) Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol 46(1):7\u201318","journal-title":"J Rheumatol"},{"key":"5270_CR123","unstructured":"Cochrane methods: ROBINS-I tool for non-randomized studies https:\/\/methods.cochrane.org\/methods-cochrane\/robins-i-tool Accessed 15 Nov 2022."}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05270-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-022-05270-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05270-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,25]],"date-time":"2023-02-25T08:06:37Z","timestamp":1677312397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-022-05270-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,13]]},"references-count":123,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["5270"],"URL":"https:\/\/doi.org\/10.1007\/s00296-022-05270-6","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,13]]},"assertion":[{"value":"5 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}